The Cambridge-based pharmaceutical company behind a variety of medicines paid its chief executive Pascal Soriot £14.7 million ...
Evening Standard on MSN12d
AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine siteWhether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary ... £450 million ...
Astrazeneca is too big and complex to base its CEO's pay on the rest of the FTSE index, according to the chair of its ...
AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...
AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...
10,000 volunteers sought for Covid-19 vaccine trials in Cincinnati EXCLUSIVE: 10,000 volunteers sought for Covid-19 vaccine trials in Cincinnati ...
The Financial Times leads on AstraZeneca's decision to scrap plans for a new vaccine manufacturing plant in Liverpool, calling it "a blow to the government's growth agenda". The paper says executives ...
In particular, the charges have targeted two lawmakers typically seen as pharma foes: Sens. Bernie Sanders (I-Vt.) and Elizabeth Warren (D-Mass.). Both will vote Tuesday on whether to advance ...
Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...
Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...
Records show a major Michigan insurance company is in talks to possibly settle more than 100 lawsuits by employees who were ...
The boss of drugmaker AstraZeneca has said he was ‘very disappointed’ with the firm’s move to scrap plans for a £450 million vaccine plant in Liverpool, but insisted the business case did ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback